Oramed Pharmaceuticals

Oramed Pharmaceuticals

Oramed Pharmaceuticals was founded in 2006 and led from its early days by CEO Nadav Kidron, who took the company public on the Nasdaq in 2013. The firm spent its first fifteen years as a clinical-stage biotechnology company pursuing an oral insulin capsule, but it never brought a product to market. In December 2021, facing a pivotal Phase 3 trial readout that would ultimately fail, Oramed's board preemptively approved a radical redeployment of the roughly $160 million in cash and short-term deposits on its balance sheet. Today Oramed does not operate as a traditional biotech. Its primary asset is a controlling equity stake in Scilex Holding Company, a commercial-stage pain-management firm, but its capital-allocation engine sits in a separate vehicle. In 2021, Oramed invested $60 million into a joint venture with South Korea's NHN Corporation, eventually deploying $600 million into what became a publicly listed digital-content and cloud-services business. The concentrated position means Oramed's market capitalization and reported earnings now swing with the performance of a single operating company outside the healthcare sector. The firm has signaled it will look for additional majority or control-oriented investments in technology and life sciences, though no subsequent deals of comparable size have been announced. Oramed's team remains small for a public company managing a concentrated equity book, and the executive group blends biotechnology veterans with professionals experienced in cross-border deal execution. In August 2023, the firm authorized a $20 million share repurchase program, signaling to the market that it views its own securities as undervalued relative to the underlying assets. The firm maintains its legacy oral insulin intellectual property and an active but de-emphasized clinical program while the majority of management attention goes to overseeing the NHN joint venture and evaluating opportunities for the remaining cash position. Oramed's structural differentiator is that it is a publicly traded biotech shell that has functionally become a publicly traded investment holding company, yet it retains its original SEC reporting status and healthcare-sector classification. This gives public-market investors indirect exposure to a private Korean tech conglomerate through a New York-listed entity — an architecture few peer firms replicate. The governance, succession, and ultimate exit strategy for the joint venture stake remain open questions for allocators evaluating the firm's long-term capital-returns profile.